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Abstract
Proteins that coat Plasmodium falciparum merozoite surface and those secreted from its apical secretory organelles are
considered promising candidates for the vaccine against malaria. In the present study, we have identified an asparagine rich
parasite protein (PfAARP; Gene ID PFD1105w), that harbors a predicted signal sequence, a C-terminal transmembrane
region and whose transcription and translation patterns are similar to some well characterized merozoite surface/apical
proteins. PfAARP was localized to the apical end of the merozoites by GFP-targeting approach using an inducible, schizont-
stage expression system, by immunofluorescence assays using anti-PfAARP antibodies. Immuno-electron microsopic studies
showed that PfAARP is localized in the apical ends of the rhoptries in the merozoites. RBC binding assays with PfAARP
expressed on COS cells surface showed that it binds to RBCs through its N-terminal region with a receptor on the RBC
surface that is sensitive to trypsin and neuraminidase treatments. Sequencing of PfAARP from different P. falciparum strains
as well as field isolates showed that the N-terminal region is highly conserved. Recombinant protein corresponding to the
N-terminal region of PfAARP (PfAARP-N) was produced in its functional form in E. coli. PfAARP-N showed reactivity with
immune sera from individuals residing in P. falciparum endemic area. The anti-PfAARP-N rabbit antibodies significantly
inhibited parasite invasion in vitro. Our data on localization, functional assays and invasion inhibition, suggest a role of
PfAARP in erythrocyte binding and invasion by the merozoite.
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Introduction
Malaria is still a major parasitic disease despite efforts spanning
more than a century to control or eradicate it. Every year about
300–500 million people get infected with malaria causing about 1–
2 million deaths [1]. Most of the clinical symptoms of P. falciparum
malaria are attributed to the continuous cycles of asexual
reproduction within the human erythrocytes that involve mero-
zoite invasion, growth and schizogony. Merozoite invasion
involves a series of highly specific, sequential interaction between
merozoite and erythrocyte surface proteins, and is a crucial step in
the parasite life cycle. Understanding the complex process of P.
falciparum merozoite invasion requires identification and charac-
terization of numerous potential parasite ligands and their
interactions with receptors on RBC. These include different
proteins on the surface of the merozoite that are possibly involved
in weak initial attachment with the RBCs, as well as those protein
that are released from the three apical secretory organelles of the
merozoite, the rhoptries, micronemes and dense granules, prior to
or during the host cell invasion and are involved in secondary
interactions [2]. A number of these antigens are considered as
promising vaccine candidates and some of these are presently at
various stages of development for clinical trials [3]. However, it has
been suggested that the most successful approach will require a
combination of antigens involved at different stages of invasion. In
addition, identification of new target antigens is also important for
the development of future vaccines, since no fully protective
vaccine has been assembled so far. Availability of P. falciparum
genome sequence and proteome data has provided new oppor-
tunity to identify novel drug and vaccine target candidates.
Recently, transcriptome analysis of the complete asexual intra-
erythrocytic developmental cycle (IDC) of P. falciparum identified
262 ORFs that showed sharp induction of expression during late
schizont stages as in case of some of the well characterized
merozoite surface/apical proteins that play role in merozoite
invasion and are the best-known malaria vaccine candidates [4].
Of the 262 ORFs, 189 are of unknown function and represent a
list of new putative vaccine candidate antigens. However it
remains to be determined whether some of these proteins are
localized on the merozoite surface/apical organelles and are
involved in merozoite invasion process. Two main characteristics
of the proteins localized on the surface or apical organelles are the
presence of an N-terminal signal sequence and the presence of a
C-terminal attachment motif such as GPI anchor or transmem-
brane region. Here, we have identified and characterized a novel
merozoite protein that contains both the N-terminal signal
sequence and a C-terminal transmembrane region. We have
localized this protein in the apical region of the merozoite and
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1732named it as apical asparagine rich protein (PfAARP). We have also
attempted to investigate the role of PfAARP during the
erythrocyte invasion.
Results
Identification and sequence analysis of PFD1105w -an
asparagine rich protein of P. falciparum (PfAARP) with C-
terminal transmembrane region
In our efforts to identify novel merozoite surface/apical
organelle proteins that might be involved in merozoite attachment
and invasion of RBC, we in silico screened P. falciparum proteome
database. P. falciparum gene PFD1105w that codes for a
hypothetical protein was selected as a candidate gene based upon
its structural motifs and stage specific transcriptional profile that is
similar to 28 other P. falciparum antigens which have been
previously shown to play role in the process of merozoite invasion
[4]. PFD1105w is a 217 amino acid long protein that contains a
putative N-terminal hydrophobic signal sequence and a C-
terminal transmembrane domain. Other interesting features
include an unusually high asparagine rich region of 63 residues
(108aa-170aa) in the C-terminal half of the protein and a run of
proline residues (PPPPPPVPPPPPP) just before the transmem-
brane region (Figure 1A). Homologs of PFD1105w were identified
from P. berghei (PB402266.00.0), P. chabaudi (PC401501.00.0), P.
vivax strain SaI-1 (Pv090210) and P. yoelii yoelii strain 17XNL
(PY06454) from the genome database. An alignment of the
predicted proteins sequences of these genes is shown in Figure 1B.
Common feature among these proteins are the presence of an N-
terminal signal sequence and a stretch of proline residues near the
C-terminus. P. berghei, P. chabaudi and P. vivax homolog also contain
asparagine rich region, which varies in length from 6–18 residues.
The homolog in P. vivax contains extra repeats of DVNG and
GNMN residues just before the asparagine rich region.
Expression of N-terminal fragment of PfAARP and
specificity of antisera
An N-terminal fragment of PfAARP (PfAARP–N; 20aa-107aa)
was cloned in pET28a vector and expressed in E. coli. The
recombinant protein was purified to homogeneity that migrated as
a single band on SDS-PAGE under reducing and non-reducing
conditions (Figure S1A). RP-HPLC analysis of the protein on a C8
column revealed single symmetrical peak (Figure S1B). Polyclonal
antibodies were raised in rabbits and mice against the recombinant
protein. The specificity of the rabbit and mice antisera was
assessed by Western blot analysis using parasite lysate from mixed
stages parasite culture. The anti-PfAARP-N antibodies recognized
a specific band (,35 kDa) in the parasite lysate (Figure S2A). The
molecular mass of PfAARP without the putative signal sequence is
22.4 kDa and its predicted pI is 4.3. The discrepancy in the
predicted mass of the protein and band on the immunoblot is
consistent with differences seen in other highly acidic proteins
[5,6]. Anti PfAARP antibodies did not react with the lysate of the
uninfected RBCs. No band was detected in parasite lysate using
pre-immune sera. (Figure S2B).
Analyses of transcription and translation of PfAARP in
asexual blood stage parasites
To ascertain the expression pattern of PfAARP during asexual
blood stage life cycle of the parasite, cDNAs were prepared from
tightly synchronized parasite cultures at 8, 16, 30, 40 and 48 h
after invasion and analyzed by real-time quantitative PCR using
gene specific primers. As shown in Figure 2A maximum transcript
level of PfAARP was observed in late schizont stages (48 h after
invasion) whereas there was no detectable transcription in the
early ring, late ring, trophozoites and early schizont stages (8, 16,
30 and 40 h after invasion respectively). Quantitative PCR from
the same set of cDNA samples were also carried out for two other
P. falciparum proteins, erythrocyte binding antigen-175 (EBA-175)
and Falcipain 2 as controls. As expected EBA-175 transcript was
also found to be maximum in cDNA samples from schizont stage
parasites whereas Falcipain-2 showed maximum transcript level in
trophozoite stage parasites. Northern blot analysis was also carried
out using total RNAs from synchronized parasite cultures at ring,
trophozoite and schizont stages, PfAARP DNA probe detected
strong ,1.8 kb message in the late schizont stage RNA (Figure 2B).
A faint signal was also detected in ring stage RNA.
Western blot analysis using anti- PfAARP antibodies with total
parasite lysates from cultures at different time point showed
expression of PfAARP protein in late-schizont/merozoite stage
parasites (Figure 2C), whereas it was not detected in parasites at
trophozoite stages. In early ring stage parasite a faint band of
PfAARP protein was observed that might represent left over
proteins after invasion of the merozoites. Our results on
transcription and translation analyses suggest that PfAARP is
expressed in the blood stage parasites specifically in the late
schizont/merozoite stages as in case of other merozoite integral
membrane proteins.
PfAARP localize to the apical end of the merozoites
To investigate the localization of PfAARP in the parasite, a
GFP-targeting approach using an inducible expression system that
directs strong, schizont-stage expression of transgene [7] was
employed (Figure 3A). Expression of the fusion protein consisting
of secreted GFP and PfAARP was activated in the transgenic
parasites, by removing the repressor drug. These transgenic
parasites were studied for localization of the PfAARP-GFP fusion
protein. Fluorescence of the GFP-fusion protein was observed in a
punctate manner in the schizonts, towards the apex of individual
merozoites (Figure 3B). Immunofluorescence assays using PfAARP
specific antisera also showed specific punctate staining in the
schizont stage parasites (Figure 3C, panel I); in the free merozoites
the staining was observed towards the apical ends (Figure 3C,
panel III). No staining was observed in the ring and trophozoite
stage parasites (not shown).
To further define the localization of PfAARP in the merozoites,
co-localization studies were carried out using antibodies against
microneme [EBA-175 and apical membrane antigen-1 (AMA-1)]
and rhoptry [cytoadherence-linked asexual gene (RhopH1/
Clag3.1)] resident proteins as well as merozoite surface protein-
1(MSP-1). Anti-MSP-1 antibody staining was found on the surface
of merozoites with PfAARP staining localized at the tip of
merozoites (Figure 4). AMA1 was present over the entire surface of
merozoites but is most densely distributed at the apical tip
(Figure 5A), whereas EBA175 tends to be restricted to the apical
end (Figure 5B) as shown earlier [8,9]. However, the PfAARP
staining did not colocalize with EBA175, and showed only partial
co-localization with AMA-1 (Figure 5A and 5B), suggesting that
the PfAARP may not be present in the micronemes. The anti-
Clag3.1 antibodies showed punctate staining in schizonts (Figure 6,
panel I) and stained the two rhoptry bulbs in the free merozoites
(Figure 6, panel II). The PfAARP staining did not colocalize with
Clag3.1 staining in the schizont (Figure 6, panel I). In the invading
merozoites, PfAARP staining was observed just above the two
rhoptry bulbs, at the apical end facing towards the RBC
membrane (Figure 6, panel II).These results suggest that PfAARP
is present at the apical end of the merozoites close to the rhoptry
PfAARP Merozoite Protein
PLoS ONE | www.plosone.org 2 March 2008 | Volume 3 | Issue 3 | e1732Figure 1. (A) Schematic representation of structure of PfAARP (Gene ID PFD1105w) gene showing location of signal sequence (SS)
and trans-membrane (TM) region. The locations of asparagine rich region and conserved proline repeat region are also marked, respective amino
acid positions are also indicated. (B) Amino acid sequence alignment of PfAARP with that of four homologs from P. berghei (PB402266.00.0) P.
chabaudi (PC401501.00.0) P. vivax strain SaI-1 (Pv090210) and P. yoelii yoelii strain 17XNL (PY06454). Amino acids that are identical in at least three of
five species (.60%) are shown in dark, amino acids that are similar in at least three of five species (.60%) or to those shown in dark, are shaded light
grey. Transmembrane region is indicated by solid bar.
doi:10.1371/journal.pone.0001732.g001
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microscopic studies using anti-PfAARP antibodies. PfAARP
staining was found to be localized in the apical ends of rhoptries,
close to the rhptry neck area, where the two rhoptries join in a
common ductule (Figure 7). No staining was found in the rhoptry
bulbs or any other organelle of the merozoites.
PfAARP binds with human RBCs through its N-terminal
region
Thefulllength PfAARPgeneand itsN-terminalhalfthat lacksthe
asparagine rich region were expressed on the surface of COS cells in
order to test their binding with the human erythrocytes. The
secretory signal sequence and transmembrane segment of Herpes
simplex virus glycoprotein D (HSV gD) gene, in the pRE4
mammalian expression vector used [10], target these protein to
the surface of transfected COS cells. A construct pHVDR22,
designed to expressP.vivaxDuffybindingproteinregionII (PvRII)in
same way [11], was used as the positive control in these assays.
Immunofluorescence assay of the transfected cells using DL6
antibodies (see materials and methods) confirmed expression of
these proteins on their surfaces. The full length PfAARP gene
(construct pRE4-PfAARP-F) showed binding with human erythro-
cytes although it’s binding efficiency were lower than that of PvRII
construct (Table 1). The N-terminal half of PfAARP (construct
pRE4-PfAARP-N) also showed RBC binding with equal efficiency
tothatoffullgene(Table1)suggestingthattheRBCbindingdomain
is present in the N-terminal half of PfAARP. Treatment of RBCs
with chymotrypsin did not affect binding with the PfAARP
expressing COS cells, whereas trypsin and neuraminidase treatment
significantly reduced the binding. These results suggest that PfAARP
binds with a receptor on RBC that is resistant to chymotrypsin
treatment but is sensitive to trypsin and neuraminidase.
Reactivity of PfAARP with human immune sera
In order to examine whether antibodies against PfAARP were
elicited during natural infection with P. falciparum, recombinant
PfAARP was examined for its reactivity with sera collected from
individuals residing in P. falciparum endemic areas. Pooled sera
from these individuals showed reactivity with the recombinant
protein on a western blot (Figure 8). In ELISA, the recombinant
protein was recognized by .50% of human sera samples that were
also positive for reactivity with recombinant PfMSP-119 protein,
another leading blood stage malaria vaccine candidate antigen
(Figure S4). These reactions were specific as no reactivity was
observed in western blot as well as in ELISA with sera from
individuals who had never been exposed to malaria.
Figure 2. Stage specific expression of PfAARP in asexual blood stage parasites. (A) Relative transcription of PfAARP assessed by real-time-
RT-PCR using total RNA extracted from tightly synchronized parasite cultures at early ring (ER), late ring (LR), trophozoite (T), early schizont (ES) and
late schizont (LS) stages (8, 16, 30, 40 and 48 h after invasion). Stage specific expression of EBA-175 and Falcipain 2 was analyzed as controls. (B)
Northern blot analysis of total RNAs isolated from synchronized parasite cultures at ring (lane 1), trophozoite (lane 2), and schizont (lane 3) stage
hybridized with labeled PfAARP probe. Equal loading of RNA in all the wells was confirmed by ethidium bromide staining of rRNAs in the gels (lower
panel). (C) Western blots analyses of equal number of highly synchronized parasites at ring (lane 1), trophozoite (lane 2) and schizont (lane 3) with
anti-PfAARP antibodies. Anti-HRPII antibodies were used to probe a blot ran in parallel to show equal loading in each wells (lower panel).
doi:10.1371/journal.pone.0001732.g002
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falciparum isolates
To assess the level of conservation of PfAARP gene sequence in
P. falciparum, PfAARP gene from five different P. falciparum strains
and five field isolates were amplified. Sequencing of these genes
showed that the N-terminal region of PfAARP is highly conserved
among these isolates and only one residue at position 103 showed
variation from NRS in four sequences; variation in the length of
asparagine repeat region was observed among these isolates that
varied from 51-63aa (25–28% of the total amino acid composition)
(Figure S5). In addition, the transmembrane region and the
proline stretch was also found to be highly conserved.
Recombinant PfAARP-N binds with RBCs and anti-
PfAARP-N antibodies inhibits this binding as well as
erythrocyte invasion by the merozoites
As the RBC binding domain of PfAARP was found to be
present in its N-terminal half, the recombinant protein corre-
sponding to this region, PfAARP-N, was tested for its ability to
bind with the human erythrocytes in an in vitro assay to ascertain
its functionality. Purified PfAARP-N and P. vivax Duffy binding
antigen region II (PvRII) bound with human erythrocytes in this
assay whereas P. falciparum DNA helicase 60 (PfD60) did not
(Figure 9A), validating that the recombinant PfAARP-N is
functionally active. In addition, binding of recombinant PfAARP
Figure 3. Localization of PfAARP to the apical end of the merozoites. (A) Schematic diagram of pTGFP-AARP plasmid construct containing
selectable marker (human DHFR) under calmodulin promoter (59 CAM), transactivator Tati-3 under MSP-2 promoter (59 MSP-2) and chimeric gene
consisting of secreted GFP (with signal sequence) and PfAARP under the control of Tet-responsive promoter. Expression of fusion gene is induced
when ahydrotetracycline (ATc) is removed from the cultures. (B) Fluorescent microscopic images of transgenic parasites at schizont stages showing
localization of PfAARP fused to a GFP reporter and expressed in an inducible system using schizont stage specific promoter. The parasite nuclei were
stained with DAPI (blue). Enlarged images of selected individual free merozoite are shown in the insets. (C) Immuno-fluorescence assay to localize
PfAARP in the schizont/merozoite stage parasites using anti-PfAARP (green) antibodies. The parasite nuclei were stained with DAPI (blue) and slides
were visualized by fluorescence microscope. S, schizont and M, free merozoites.
doi:10.1371/journal.pone.0001732.g003
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treatments, as in case of COS cell surface binding assays
(Figure 9A). Further, ability of the anti- PfAARP-N antibodies to
inhibit binding of PfAARP-N with RBCs was assessed. As shown
in Figure 9B, antibodies purified from rabbit immunized with
PfAARP-N inhibited RBC binding of PfAARP-N in a dose
dependent manner. No inhibition was observed with IgG purified
from pre-immune sera.
The ability of anti-PfAARP-N antibodies to inhibit parasite
invasion was assessed by an in vitro parasite growth inhibition assay.
Anti-PfMSP-142 antibodies were used as positive control. As
shown in Table 2, anti-PfAARP-N antibodies significantly (up to
70%) inhibited the parasite growth in a concentration dependent
manner. The invasion inhibition by anti-PfAARP-N antibodies
was comparable to the inhibition by anti-PfMSP-142 antibodies.
Discussion
Availability of the predicted proteome and transcriptome data
for P. falciparum has provided an impetus to find novel drug targets
and vaccine candidate antigens. In the present study we have
identified PfAARP as one such candidate antigen. Transcriptome
analysis of stage specific asexual blood stage parasites grouped
PfAARP with 28 other P. falciparum proteins that are involved in
the process of merozoite invasion [4]. We have confirmed
expression of PfAARP specifically at late schizont/merozoite stage
by quantitative real-time PCR and western blot analysis,
suggesting it to be essentially a merozoite protein. PfAARP
contains an N-terminal signal peptide and a C-terminal trans-
membrane region. The N-terminal signal sequence in different P.
falciprum proteins is responsible for entry of the proteins into the
ER-trans Golgi network (TGN) secretory system and then these
proteins get further distributed in to different trafficking routes
depending upon additional signals [12,13,14,15]. A number of
merozoite proteins that are localized on its surface or reside in the
apical secretory compartments, harbor N-terminal signal sequenc-
es. These protein after passing through the secretory pathway, get
targeted to their final destination such as merozoite surface,
rhoptries or micronemes [12,13,16]. Many of these merozoite
surface proteins (MSPs) such as MSP-1, -2, -4, and -5 attach to the
plasma membrane via a C-terminal glycosylphosphatidyl inositol
(GPI) whereas all known micronemal proteins are type I integral
membrane proteins that contain a C-terminal transmembrane
domain and a short cytoplasmic domain [2]. The rhoptries also
contain several resident proteins that either have a transmembrane
region, such as rhoptry-associated proteins 1 (RAP1) [17] or have
a GPI anchor such as rhoptry associated membrane antigen
(RAMA) [18].
The structural features of PfAARP i.e. presence of a C-terminal
transmembrane region in addition to the N-terminal hydrophobic
signal sequence and its stage specific expression pattern, led us to
speculate that it might be a putative merozoite surface/apical
protein. To confirm this hypothesis, we studied localization of
PfAARP by GFP targeting approach in a transgenic parasite line.
A number of studies have used this approach to explore the
localization and trafficking of the parasite proteins [14,19,20,21].
However, correct timing of expression of the transgene in P.
falciparum transgenic parasite lines has been shown to be a
prerequisite for protein sorting and correct subcellular localization
[12,22]. In addition, constitutive over expression of some
transgenes encoding merozoite surface proteins might be toxic to
the parasite [7]. Therefore, to localize PfAARP in the parasite, a
secreted GFP- PfAARP fusion protein was expressed in the
parasite under the control of a schizont stage promoter of MSP-2
Figure 4. Immunofluorescence assay to localize PfAARP by coimmuno-staining of P. falciparum parasites with anti-PfAARP (green)
and anti-MSP-1 (red) antibodies. The parasite nuclei were stained with DAPI (blue) and slides were visualized by fluorescence microscope. The
apical ends of the merozoites have dense structure. MSP-1 staining was found around the merozoites and the PfAARP was localized at the apex of the
merozoites. MS, mid schizont; LS, late schizont and M, free merozoites.
doi:10.1371/journal.pone.0001732.g004
PfAARP Merozoite Protein
PLoS ONE | www.plosone.org 6 March 2008 | Volume 3 | Issue 3 | e1732and a tetracycline-regulated transactivator, using a recently
developed transfection vector [7,23]. The temporal expression of
the transgene in this system mimics that of MSP-2 [7] which has a
similar transcriptional profile to PfAARP. The GFP- PfAARP
fusion protein expressed in the transgenic parasite using this
approach was found to be localized towards the apical end of the
merozoites. Immunofluorescence assays and colocalization studies
further confirmed presence of PfAARP at the apical end of the
merozoites. Merozoites harbour a secretory complex at their
apical end that consists of organelles like rhoptries and
micronemes. These organelles contain many of the key proteins
needed for directional attachment and invasion of the merozoite
[2,24]. After the release of merozoites from schizont and during
the invasion process, contents of both rhoptries and micronemes
get excreted through the ductules at the neck of the rhoptry
[25,26]. Rhoptries contain a number of proteins including high
molecular mass proteins complex, RhopH complex, membrane
associated Rhoptry proteins (RAMA) and rhoptry associated
proteins (RAP1, RAP2 and RAP3) that are focus of interest as
vaccine candidates. RhopH complex proteins localize to the basal
bulb of the rhoptries [27] and are involved in erythrocyte binding
and in establishment of parasitophorous vacuole [28]. RAMA has
been shown to be localized to inner face of the rhoptry bulb
membrane in close apposition of RhopH3 and RAP1 [18].
Figure 5. Spatial localization of PfAARP by co-immunostaining studies with microneme resident proteins AMA-1 (A) and EBA-175
(B). P. falciparum parasites were co-immunostained with anti-PfAARP (green) and anti-AMA-1 or anti-EBA-175 (red) antibodies. The parasite nuclei
were stained with DAPI (blue). Both the microneme markers and PfAARP showed punctate staining in the schizonts. In the late schizonts and
merozoites, AMA-1 was present over the entire surface of the merozoites but is most densely distributed at their apical tip, whereas EBA-175 staining
was restricted to the apical ends. Enlarged image of selected individual merozoite is shown in the inset. MS, mid schizont; LS, late schizont and M, free
merozoites.
doi:10.1371/journal.pone.0001732.g005
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merozoite invasion including duffy binding like proteins, EBA-175,
EBA-140 and EBA-180, that binds with the host RBC in a sialic
acid dependent manner [2]. In the present study, PfAARP did not
colocalize with any of the micronemal and rhoptry proteins tested,
and was found to be discretely localized above these apical
secretory structures in the free merozoites. Our results of immuno-
electron microscopic studies clearly show that PfAARP is situated
in the apical ends of the secretory organelle rhoptries in the
merozoites. Some other P. falciparum proteins have been localized
to the rhoptry neck that may play role in binding and invasion of
the merozoites. These include rhoptry neck protein PfRON4 that
is a homologue of Toxoplasma gondii rhoptry neck protein
TgRON4. PfRON4 forms a complex with PfAMA1 during its
secretion in the course of merozoite invasion [29]. TgRON4 also
interacts directly with the TgAMA1 and participate in the
formation of moving junction, a circumferential zone which forms
at the apical tip of the parasite during its invasion in the host cell
[30]. P. falciparum also expresses a family of proteins (PfRh1,
PfRh2a, PfRh2b, and PfRh4) that are orthologs of P. vivax
reticulocyte binding proteins, these proteins also localize in the
rhoptry neck at the merozoite apical end [2,31,32]. Recently, a
GPI anchored merozoite protein Pf34 was also found to be
localized to the rhoptry neck [33].
Since a number of merozoite apical proteins play role in binding
and invasion of RBC by the merozoites [2], we tried to assess a
possible role of PfAARP in RBC binding. Our results of binding
assays with COS cell surface expressed PfAARP suggest that
PfAARP is involved in binding of the merozoite with the host
RBC. A number of surface proteins are expected to be involved in
initial binding of the merozoite with the RBC whereas proteins of
apical organelles such as the members of DBL family and
homologs of reticulocyte binding proteins are involved in binding
Figure 6. Spatial localization of PfAARP by co-immunostaining studies with rhoptry resident protein Clag3.1. P. falciparum parasites
were coimmuno-stained with anti- PfAARP (green) and anti-Clag3.1 (red) antibodies. The parasite nuclei were stained with DAPI (blue). Clag3.1
staining was present in the rhoptry bulb in the free and invading merozoites (lower panel). PfAARP was localized just above these two rhoptry bulbs
towards the apex of the merozoites. Enlarged image of merozoite invading in the host erythrocyte is shown in the inset. LS, late schizont and M, free
merozoites.
doi:10.1371/journal.pone.0001732.g006
Figure 7. Localization of PfAARP by immuno-electron micros-
copy. Ultra thin sections of P. falciparum parasites at schizont/
merozoite stages were labeled with anti-PfAARP antibody and gold
labeled secondary antibody. Labeling was observed in the apical end of
the rhoptries in merozoite. Scale bar=250 nm.
doi:10.1371/journal.pone.0001732.g007
Table 1. Binding of normal and treated erythrocytes with
Cos-7 cells expressing full length PfAARP or its N-terminal
fragment, PfAARP-N
Construct No. of rosettes
1
Untreated Trypsin Neuraminidase Chymotrypsin
PfAARP 52 (68) 11 (65) 16 (64) 50 (610)
PfAARP-N 54 (63) 8 (66) 14 (66) 52 (68)
pHVDR22
2 70 (69) N/A N/A 5 (62)
1The number of COS-7 cells with rosettes of bound erythrocytes was scored in
20 fields at 6200 magnification. Number of rosettes of each experiment was
normalized according to respective transfection efficiency to 5%. Mean value
of 3 independent experiments is reported with standard deviation.
2Construct designed to express P. vivax Duffy binding protein region II (PvRII)
[11]
doi:10.1371/journal.pone.0001732.t001
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number of receptors on the erythrocyte surface that interact with
these ligands including glycophorin A, B and C and unknown
receptors E, X, Y and Z. These receptor–ligand interactions
between the merozoite surface/apical proteins and erythrocyte
surface receptors are characterized by their enzyme sensitivities to
neuraminidase, trypsin, and chymotrypsin [31,34]. We found that
PfAARP binds with RBC in a chymotrypsin resistant manner, and
shows sensitivity to trypsin and neuraminidase treatments
suggesting that it utilizes a receptor similar to Glycophorin A or
C on the RBC surface. Taken together the results of localization
and binding assays suggested that the PfAARP is involved in
binding of the merozoite after re-orientation during the process of
invasion. Further the binding domain was localized in the N-
terminal half, suggesting that the repeat structure in the C-
terminal half has no role in RBC binding. Repeat regions are
common in Plasmodium proteins located on the merozoite surface
or in the apical secretory organelles [18,31,35,36]. Although the
role of these repeat regions is not clear, it has been suggested that
these might act as immunodominant epitopes that may contribute
to malaria immunity [37].
Malaria proteins show extensive polymorphism that is suggested
to be one of the main strategies of the parasites to evade host
immune mechanisms, and the antigens that are under natural
immune pressure tend to have higher levels of polymorphism.
[38,39]. On the other hand, it is also shown that residues that
show polymorphism due to immune pressure are different than the
functionally critical domains which are relatively conserved and
are more suitable target for vaccine development [40,41]. Having
found out that PfAARP is involved in RBC binding, we assessed if
it is also conserved across different P. falciparum strains and field
isolates. Sequencing of PfAARP gene from different P. falciparum
strains and field isolates showed that it has evolutionary conserved
N-terminal half that may signify the functional importance of the
N-terminal region of PfAARP for the parasite survival. These
results in combination with our RBC binding assays suggest that
PfAARP plays a significant role in binding and invasion of RBC by
the merozoite.
A number of merozoite surface antigens are proposed to elicit
protection against the parasite by antibody mediated inhibition of
merozoite invasion [42]. We assessed if there is any immune
response generated against PfAARP during natural exposure to P.
falciparum. The asparagine repeat region present in PfAARP is
known to be common among many parasite proteins [43,44,45].
Therefore to avoid detection of cross reactive antibodies against
these regions, we used recombinant protein corresponding to N-
terminal half of the gene, PfAARP-N, that contains the functional
RBC binding domain. Recombinant PfAARP-N was recognized
by immune sera from individuals residing in P. falciparum endemic
areas, indicating that it contains epitope(s) that are target of
antibody response generated during natural exposure to P.
falciparum. Presence of anti-PfAARP antibodies in human immune
sera and conservation PfAARP gene across different isolates/strain
suggest that this antigen may induce effective host-immune
response against the parasite. We further evaluated the efficacy
of rabbit antibodies generated against the PfAARP-N to inhibit
merozoite invasion. The recombinant PfAARP-N was functional
with respect to its binding activity with human erythrocytes and
this binding was inhibited by anti- PfAARP-N antibodies in a dose
dependent manner. These results suggested that binding inhibitory
antibodies are present in the rabbit immune sera that block
receptor binding function of PfAARP. These antibodies also
significantly inhibited invasion of the erythrocytes by parasites in a
dose dependent manner. Our invasion inhibition data using
binding inhibitory anti- PfAARP antibodies suggest that binding of
PfAARP to the RBC is a vital step during the process of merozoite
invasion and support PfAARP to be a putative vaccine/drug target
candidate. Owing to the complexity of the invasion process, it is
essential that strategies for preventing malaria disease that are
directed against merozoite invasion should include such parasite
proteins that play important roles during different steps of invasion
using diverse ligand-receptor interactions.
Figure 8. (A) Anti-PfAARP antibodies are present in human
immune sera from P. falciparum endemic area. Western blot
analysis showing reactivity of recombinant PfAARP-N (lane 1) with
human immune sera, PfMSP-119 (lane 2) was kept as a positive control.
(B) Coomassie blue stain SDS- poly acryl amide gel ran in parallel.
doi:10.1371/journal.pone.0001732.g008
Figure 9. Erythrocyte binding assay using recombinant
PfAARP-N and binding inhibition by anti-PfAARP-N antibodies.
(A) Western blot using monoclonal anti penta histidine antibodies
showing detection of recombinant proteins in elutes from the RBC
binding assays of protein PfDH60 (negative control; lane 1), PvRII (lane
2) and PfAARP-N (lane 3) using untreated human RBC, and in elutes
from similar binding assays of PfAARP-N using human RBCs treated with
trypsin (lane 4), neurminidase (lane 5) and chymotrypsin (lane 6). (B)
Western blot of elutes from the RBC binding assays with the
recombinant PfAARP-N protein pre-incubated in RPMI alone (lane 1)
or with antibodies purified from pre-immune sera (100 mg, lane 2) and
anti- PfAARP antibodies purified from rabbit immune sera (10, 25, 50
and 100 mg, lane 3–6). Equal amount of recombinant protein was used
in each assay.
doi:10.1371/journal.pone.0001732.g009
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Parasite culture, transfection plasmid construct and
parasite transfection
Plasmodium falciparum strains 3D7 were cultured on human
erythrocytes (4% hematocrit) in RPMI1640 media (Invitrogen)
supplemented with 10% O+ human serum using standard
protocol [46]. Parasite cultures were synchronized by two sorbitol
treatments at 4 h apart following Lambros and Vanderberg [47].
To generate a transfection vector construct, the PfAARP gene was
amplified from P. falciparum 3D7 genomic DNA using primers:
500A- 59 CCG ACG CGT ATA TTG AGG AAT AAC AAA
AGT CAT AAC 39 and 501A- 59 CGG ACT AGT TTA GGG
TAC TCC GAT TAA TTT TAA ACC 39. Amplified PCR
product was digested with MluI and SpeI restriction enzymes and
cloned in frame to the C-terminus of secreted GFP in the MluI and
SpeI sites of the transfection vector [5] to give pTGFP-AARP
transfection vector. This vector contains fusion protein of secreted
GFP and PfAARP under tetracycline-inducible expression system.
Synchronized P. falciparum 3D7 ring stage parasites were
transfected with 100 mg of purified plasmid DNA (Plasmid Maxi
Kit, Qiagen, Valencia, CA) by electroporation (310V, 950 mF)
[48] and the transfected parasites were selected over 2.5 nM of
WR99210 drug in presence of 5 mM Anhydrotetracycline.
Isolation of DNA, total RNA, real time quantitative PCR,
northern blot analysis
The genomic DNA was isolated from in vitro culture of P.
falciparum following a standard protocol [49]. Total RNAs were
isolated from synchronized P. falciparum 3D7 parasite cultures using
mini RNA isolation kit (Qiagen). An aliquot of 50 ng of total RNA
was used to synthesize cDNA using cDNA synthesis kit (Invitrogen)
following manufacturer’s recommendations. Gene specific primers
were designed using Beacon Designer4.0 software, for the genes
PfAARP (535A, 59 AAc GAA TGA AGA AGA GGA AGG 39 and
536A, 59TCT CAT ACT TAA ATC AAT AAA GGA ACC 39),
EBA175 (EBA175RTF: 59 AAT TTC TGT AAA ATA TTG TGA
CCA TAT G 39 and EBA175RTR: 59GAT ACT GCA CAA
CAC AGA TTT CTT G 39) and Falcipain 2 (Fal2F 59-
GCTTGTAGGTTTT GGTATGAAAGAA-39 and Fal2 R 59
AGATAGGTCCCTTTTTAAAATACTATTGAC-39) [50]; 18S
rRNA control primers (18SF 59-GCTGACTACGTCCCTGCCC-
39; 18SR 59-ACAATTCATCATATCTTTCAATCGGTA-39)
were used following Blair et al. [51]. Quantitative real time PCR
were carried out in triplicate using the iCycler version 3.0
(Bio-Rad); each reaction was containing equal amount of
cDNA, 100 ng of both the gene specific primers and 16 SYBR
Green PCR mix (Bio-Rad). Threshold cycle (Ct) values were
calculated by using iCycler software. Standard curves for each
gene were obtained by using different dilutions of wild-type gDNA
(100–1 ng) as template, and these standard curves were used to
determine genome equivalents of Ct values for every gene and 18S
rRNA in each RNA sample [51]. Genome equivalents of each
gene were normalized using that of 18S rRNA for all the RNA
samples.
Expression plasmid construct, expression and purification
of recombinant protein, RP-HPLC and Generation of
polyclonal anti-sera
An N-terminal fragment of PfAARP gene (20aa- 107aa) was
amplified by PCR from P. falciparum 3D7 genomic DNA using
primers 513A (59 GGC GGA TCC ATA TTG AGG AAT AAC
AAA AGT CAT 39) and 514A (59 GAC AAG CTT ATC TTC ATT
GTC TTC TTC ATC 39). The amplified fragment was digested
with restriction enzymes BamHI and HindIIII and cloned in the
BamHI and HindIII sites of pET28a expression vector (Novagen).
The resultant plasmid pET28a-PfAARP-N was transformed into
expression cells BLR(DE3) for expression of the recombinant
protein. These E. coli BLR(DE3) cells were grown in Luria broth
containing tetracycline (25 mg/ml) and kanamycin (100 mg/ml) at
37uC with shaking to an OD600 of 0.6–0.7 and expression of
recombinant protein was induced with isopropyl-b-thioglactopyr-
anoside (IPTG) at a final concentration of 1 mM. The cultures
were further grown at 37uC for 3–4 h and the E. coli cells were
harvested by centrifugation. The cell pellet was suspended in lysis
buffer (20 mM Tris pH 8.0, 500 mM NaCl, 1 mM benzamidine
hydrochloride and 1% Tween 20) and the bacterial cells were
lysed by sonication (Torebeo Ultrasonic Processor 36800, Cole
Parmer). The lysate was centrifuged at 15,0006g for 30 min at
4uC and the supernatant was incubated with Ni-nitrilotriacetic
acid (Ni
2+-NTA) agarose resin (Qiagne), pre-equilibrated with the
lysis buffer, at 4uC for 1 hr. The suspension was applied to a
column and washed with 10 bed volumes of the wash buffer
(20 mM Tris-HCl, pH 8.0, 250 mM NaCl 5 mM imidazole). The
bound protein was eluted with 15 ml of elution buffer (20 mM
Tris and 250 mM NaCl) containing 50 mM imidazole. The
Table 2. Inhibition of P. falciparum invasion of erythrocytes by purified rabbit anti-PfAARP antibodies. Anti-PfMSP-142 rabbit
antibodies were used as a control.
Group % of parasitaemia
1 % of invasion inhibition
4
Concentration of IgG (mg/ml)
2 Concentration of IgG (mg/ml)
0.5 0.25 0.125 0.0625 0.5 0.25 0.125 0.0625
Adjuvant
control
5.66 (60.12)
3 5.76 (61.25) 6.13 (60.32) 5.34 (60.58) - - -
PfAARP
immune
1.73 (60.31) 2.63 (60.58) 3 (60.7) 3.24 (6013) 69.41 54.34 51.10 39.4
MSP-142
immune
2.07 (60.12) 1.93 (60.12) 2.86 (60.31) 3.4 (60.01) 63.50 66.50 53.30 36.3
1Parasitaemia is the average of triplicate wells.
2Final concentration of IgG in a well
3Standard deviation
4Calculated against wells with antibodies from adjuvant control (chi-squares test, P#0.01).
doi:10.1371/journal.pone.0001732.t002
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the recombinant protein with a clear single band were pooled and
the protein concentration was determined using the BioRad
protein assay system (BCA method) and a standard curve of
bovine serum albumin. The purified protein was analyzed by
reverse phase HPLC on C8 column using a linear gradient of 10 to
90% acetonitrile in water containing 0.05% trifluoroacetic acid.
To generate polyclonal anti-sera against PfAARP, female
BALB/c mice were immunized (on day 0) with the purified
recombinant protein (25 mg) formulated in complete Freund’s
adjuvant (Sigma, USA). The mice were administered two booster
doses (day 14 and 28) of the proteins formulated in Freund’s
incomplete adjuvant. The mice serum was collected 10 days after
the second boost. Two New Zealand white rabbits (3 months old)
were immunized in the same way with 250 mg of recombinant
protein (on day 0) and administered two booster doses (on day 28
and 49). The rabbit sera were collected on day56.
ELISA and Western blot analyses
Antibody response in mice, rabbits and human serum samples
were quantified by ELISA. Briefly, wells of flat bottom microtitre
plates (Dynatech) were coated with 100 ng of the recombinant
protein in 0.06 M carbonate-bicarbonate buffer (pH 9.6). The
plates were washed thrice with 0.05% tween in PBS (PBS-T) for
5 minutes each and blocked with 5% skimmed milk in PBS for 1 h
at room temperature. The antigen-coated wells were sequentially
incubated with the appropriate dilutions of respective test sera and
optimally diluted mouse anti-human-IgG horse radish peroxidase
(HRP) labeled secondary antibody. The enzyme reaction was
developed with o-phenylenediamine as a chromogen and
hydrogen peroxide as a substrate prepared in citrate phosphate
buffer, pH5.0. The reaction was stopped with 8N H2SO4 and
OD490 was measured using an ELISA micro-plate reader
(Molecular devices). Serial dilution of mice and rabbit sera
samples were analyzed in triplicate by ELISA and the last dilution,
at which the OD490nm was greater than the mean OD490nm plus
two standard deviations from the pre-immunization serum were
defined as the endpoint titer.
IgG specific for PfAARP in immune human sera samples were
also assayed by ELISA using recombinant protein PfAARP-N.
Each test serum sample was assayed at a dilution of 1:20 against
the proteins in duplicate with normal human sera as control as
previously described [52]. The positive cut-off value was calculated
as the mean OD value of the normal controls plus two standard
deviations. Same battery of sera samples were used at a dilution of
1:100 to determine the anti-PfMSP-119 IgG antibody responses as
previously described by Sachdeva et al. [53].
For western blot analyses, parasites were isolated from tightly
synchronized cultures at different developmental stages by lyses of
infected erythrocyte with 0.15% saponin. Parasite pellets were
washed with PBS, suspended in Laemmli buffer, boiled,
centrifuged, and the supernatant obtained was separated on
12% SDS–PAGE. The fractionated proteins were transferred
from gel onto the nitrocellulose membrane (Amersham) and
blocked in blocking buffer (16PBS, 0.1% Tween-20, 5% milk
powder) for 2 h. The blot was washed and incubated for 1 h with
primary antibody [mouse anti-PfAARP (1:500); rabbit anti-
PfAARP (1:1000); rabbit anti HRPII (1:2000)] diluted in dilution
buffer (16PBS, 0.1% Tween-20, and 1% milk powder). Later, the
blot was washed and incubated for 1 h with appropriate secondary
antibody (anti-rabbit or anti-mouse, 1:2000) conjugated to HRP,
diluted in dilution buffer. Bands were visualized by using ECL
detection kit (Amersham).
COS cell expression plasmid constructs, COS cell culture,
transfection and immunofluorescence assays
To generate COS cell expression plasmid constructs, two
fragments of PfAARP one corresponding to complete gene except
the signal sequence and the transmembrane region (F, 20aa-
190aa), and other representing the N-terminal half (N, 20aa-92aa)
were amplified from the genomic DNA using primers 554A (59
CCG CAG CTG ATA TTG AGG AAT AAC AAA AGT C 39)
and 556A (59 CGG GGG CCC TGG AGG TGG GGG AGG
TAC 59) for F fragment, and 554A and 555A (59 CGG GGG
CCC ATC TTC ATT GTC TTC TTC 39) for N fragment. The
amplified PCR products were digested with PvuII and ApaI
restriction enzymes and cloned into PvuII and ApaI sites of pRE4
vector [10] in frame with the signal sequence and transmembrane
segment of HSV gD. The resultant plasmids were labeled as
pRE4-PfAARP-F and pRE4-PfAARP-N respectively.
The COS-7 cells were cultured in Dulbecco modified Eagle
medium (DMEM; Invitrogen) with 10% heat-inactivated fetal calf
serum (FCS) in a humidified CO2 (5%) incubator at 37uC. Fresh
monolayers of 40% to 60% confluent COS-7 cells growing in 35-
mm diameter wells were transfected with 2 to 4 mg plasmid DNA
using Lipofectamine Plus reagent (Invitrogen) following manufac-
turer’s instructions. To detect expression of the fusion proteins on
the surface of transfected COS-7 cells and to calculate the
transfection efficiency, immunofluorescence assays were per-
formed , 36 to 40 hours after transfection, following Chitnis and
Miller [11], using mouse monoclonal antibody DL6 (kindly
provided by Drs Roselyn Eisenberg and Gary Cohen), which
reacts with amino acids 272 to 279 of HSV gD.
Erythrocyte binding assay with COS-7 cells expressing
PfAARP on the surface
Human erythrocytes were washed three times in incomplete
RPMI1640 media (Life Technologies, Inc.) and re-suspended in
RPMI1640. Erythrocytes were treated with neuraminidase,
chymotrypsin and trypsin as described earlier [11]. Briefly, for
neuraminidase treatment 5.5 ml of a 5% (vol/vol) suspension of
the washed human erythrocytes in incomplete medium was
incubated twice with 3 milliunits of neuraminidase (Vibrio cholerae;
Sigma) for 1 h at 37uC each time. For trypsin treatment, washed
human erythrocytes were incubated with 1 mg/ml tosyl-phenyl-
alanine-chloromethyl-ketone-treated trypsin (Sigma) for 1 h at
37uC. For chymotrypsin treatment, erythrocytes were incubated
with 1 mg/ml a-chymotrypsin (Sigma) for 1 h at 37uC.
COS-7 cells transfected with constructs pRE4-PfAARP-F and
pRE4-PfAARP-N were tested for binding to normal, neuramin-
idase-treated, chymotrypsin-treated and trypsin-treated human
erythrocytes, 36 to 40 hours after transfection, following Chitnis
and Miller [11]. COS-7 cells transfected with plasmid pHVDR22
[11] were used as positive control. The number of rosettes of
erythrocytes bound to transfected COS-7 cells was scored in 20
fields at 2006magnification for each set. A cluster of 8 or more
erythrocytes bound to a COS-7 cell was scored as a rosette. The
number of rosettes observed was normalized for transfection
efficiency of 5% for all the sets.
Erythrocyte binding assay (EBA) with recombinant
protein and antibody mediated inhibition of binding
Erythrocyte binding assays were carried out using recombinant
PfAARP following Pandey et al [54]. About 100 ml of packed
volume of normal human erythrocytes, previously washed with
RPMI, were suspended in RPMI containing 10% FCS and 20 mg
of recombinant protein to a final volume of 500 ml. This
PfAARP Merozoite Protein
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constant shaking. The reaction mixture was layered over
dibutylpthalate (Sigma) and centrifuged to collect erythrocytes.
Bound protein was eluted from the erythrocytes with 300 mM
NaCl, separated by SDS-PAGE and detected by Western blotting
using a commercially available mouse monoclonal antibody to
penta-histidine (Qiagen). Recombinant P. vivax Duffy binding
antigen region II (PvRII) and P. falciparum DNA helicase 60
(PfD60) were used as positive and negative controls respectively, in
the RBC binding assay.
Efficacy of anti-PfAARP antibodies to inhibit the binding of
PfAARP with human erythrocytes was also assessed in similar
manner. Briefly, aliquots of recombinant protein (20 mg) were
incubated at room temperature for 1 h with different amounts
(25–100 mg) of IgG purified from the sera of rabbit immunized
with PfAARP. After incubation these recombinant protein samples
were used for erythrocyte binding assays. IgG purified from pre-
immune sera were used as control.
Fluorescence microscopy and indirect
immunofluorescence assay
P. falciparum culture transfected with pTGFP-AARP was
synchronized by two consecutive sorbitol treatments with 4 h gap
between each treatment. Ahydrotetracycline was removed from the
parasite cultures 72 h prior to live imaging (in the presence of
2.5 nM WR99210) to allow expression of the GFP fusion protein.
Parasites at different developmental stages were collected for
fluorescence microscopy and stained with DAPI at a final
concentration of 2 mg/ml for 30 min at 37uC, prior to imaging.
Fluorescence from DAPI and GFP was observed and captured from
live cells using a Nikon TE 2000-U fluorescence microscope.
Indirect immunofluorescence assays were performed on P.
falciparum 3D7 parasite lines as described earlier [55,56]. Thin
smears of P. falciparum infected erythrocytes were made on glass slide
and fixed with a mixture of methanol/acetone. Slides were blocked
in blocking buffer (16PBS, 10% FCS) for 2 h at 37uC. After
blocking, slides were incubated with primary antibody diluted in
blocking buffer (mice anti-PfAARP, 1:100; rabbit anti-AMA-1
1:300; rabbit anti-EBA-175, 1:300; rabbit anti-Clag3.1 1:300;
rabbit anti-MSP-1, 1:500) for 1 h at 37uC. Slides were washed with
16PBS for 1 h and incubated with appropriate secondary antibody
conjugated to fluorescent dye (FITC or Cy3; dilution 1:100) for 1 h.
The slides were stained with DAPI for 30 min at 37uC at final
concentration of 2 mg/ml and then washed twice in 16 PBS–
Tween 0.05%, once in 16PBS and mounted on a cover slip in the
presence of anti fade mounting media (Bio-Rad). The slides were
viewed on Nikon TE 2000-U fluorescence microscope.
Cryo-Immuno-electron microscopy
Immuno-electron microscopy was carried out on P. falciparum
3D7 schizont stages parasites. Parasites were fixed in 4%
paraformaldehyde, 0.04% glutaraldehyde in 16 PBS at 4uC for
1 h and subsequently embedded in gelatin, and infiltrated with a
cryo preservative and plasticizer (2.3 M sucrose/20% polyvinyl
pyrrolidone). After freezing in liquid nitrogen, samples are
sectioned with a Leica Ultracut UCT cryo-ultramicrotome (Leica
Microsystems Inc., Bannockburn, IL) at 260uC. Ultra thin
sections were blocked with 5% fetal bovine serum and 5% normal
goat serum in 16PBS for 30 min and subsequently stained with
anti-PfAARP antibody (1:100 dilution in blocking buffer), washed
thoroughly and incubated with 18 nm colloidal gold-conjugated
mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West
Grove PA) for 1 hr. Sections were stained with 0.3% uranyl
acetate/1.7% methyl cellulose and visualized under JEOL
1200EX transmission electron microscope (JEOL USA Inc.,
Peabody, MA). All labeling experiments were conducted in
parallel with controls omitting the primary antibody or using
pre-immune sera as primary antibodies.
IgG purification
Total IgG was purified from the sera of rabbits immunized with
PfAARP-N and also from rabbits immunized with adjuvant alone,
following the procedure described previously [53]. Briefly, sera
samples were loaded on a protein G-Sepharose column (Amarsham),
equilibrated with the binding buffer (100 mM Tris-HCl, pH 8.0).
The column was washed with 10-column volumes of the binding
buffer. The bound IgG was eluted with 0.2 M glycine-HCl, pH 3.0
and the fractions were analyzed on SDS-PAGE. The fractions
containing purified IgG were pooled and dialyzed against RPMI.
Human sera samples
The sera samples were collected from individuals residing in a P.
falciparum endemic area (Orissa, India) [57]. Sera samples were also
collected from healthy individuals with no known history of malaria
and who have never visited malaria transmission areas. The sera
were collected with the consent of these individuals and approval of
Human Volunteers Research Ethical Committee of ICGEB.
Sequencing of PfAARP allele from different P. falciparum
isolates
The entire PfAARP gene, excluding predicted signal sequence,
was PCR amplified using high fidelity PCR enzyme mix (MBI
Fermentas) and total genomic DNAs of five different P. falciparum
strains and five field isolates (Table S1) using 500A/501A-primer
pair. The resulting PCR products (,600–650 bp) purified by the
PCR purification kit (Qiagen) were used for direct sequencing. For
each DNA sample, amplified products from two separate PCR
were sequenced in both the forward and reverse direction using
big dye termination chemistry. The sequence data were aligned
using Seqman II and the ClustalW algorithm in MegAlign
(DNAStar, Madison, WI).
In vitro parasite growth inhibition assay
Growth inhibition assay was performed as previously described
[53,58]. Briefly, tightly synchronized P. falciparum 3D7 parasites at
schizont stage were cultured in 96 well plates in which hematocrit
and parasitemia were adjusted to 2.0% and 0.5% respectively. IgG
purified from sera of rabbit immunized with PfAARP or adjuvant
alone, were added to the parasite cultures at final concentrations of
0.5, 0.25, 0.125 and 0.0625 mg/ml. The cultures were incubated
for 20 h to allow for schizont rupture and merozoite invasion. Each
assay was performed in triplicate and the experiment was repeated
twice. For microscopic analysis, smears were made from each well,
stained with Giemsa, and the numbers of ring stage parasites per
5000 RBCs were determined and percentage ring stage parasitemia
was calculated to assess the parasite invasion. Percentage inhibition
of the parasite invasion was calculated using the following formula:
% Inhibition~1  Invasion ½ anti   PfAARP sera ðÞ =
Invasion Adjuvant alone ðÞ   |100
Supporting Information
Figure S1 Expression and purification of N-terminal fragment of
PfAARP. (A) SDS-PAGE showing purified recombinant N-
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and non-reduced conditions (lane 2). (B) Reverse-phase HPLC
profile of purified PfAARP-N showing a single homogenous
population of recombinant protein that eluted as a single sharp
peak.
Found at: doi:10.1371/journal.pone.0001732.s001 (3.15 MB TIF)
Figure S2 Reactivity and specificity of anti-PfAARP rabbit
antisera. (A) Western blot analysis of total parasite lysate (lane 1)
and uninfected RBCs(lane 2) using anti-PfAARP-N antibodies
detected a single specific band of ,35 kDa in the parasites. (B)
Western blot analysis of total parasite lysate using rabbit pre-
immune sera. (C) Immuno-fluorescence assay showing reactivity of
anti-PfAARP rabbit antibodies (red) with the schizont/merozoite
stage parasites. The parasite nuclei were stained with DAPI (blue)
and slides were visualized by fluorescence microscope. S, schizont
and M, free merozoites. (D) Immunofluorescence assay showing
co-immunostaining of P. falciparum transgenic parasites at schizont
stages with anti-GFP (green)and anti-PfAARP rabbit (red)
antibodies. The parasite nuclei were stained with DAPI (blue)
and slides were visualized by fluorescence microscope.
Found at: doi:10.1371/journal.pone.0001732.s002 (8.94 MB TIF)
Figure S3 Expression of PfAARP on COS cells surface and
RBC binding assay. (A) Immunofluorescence assay of COS cells
trasfected with pRE4-PfAARP construct, using anti-PfAARP
antibodies. (B) RBC binding assay of transfected COS cells using
human erythrocytes.
Found at: doi:10.1371/journal.pone.0001732.s003 (3.20 MB TIF)
Figure S4 Scatter plots representing ELISA results using sera
from individuals residing in P. falciparum endemic areas; each
serum was tested in triplicate against recombinant PfAARP-N (A),
recombinant PfMSP-119 (B) was kept as positive control. The
horizontal bars indicate the cutoff value (mean +2SD of negative
controls) of the reactivity for positive responders. Sera samples
from healthy individuals with no past history of malaria and who
have never visited malaria transmission areas were used as
controls.
Found at: doi:10.1371/journal.pone.0001732.s004 (5.40 MB TIF)
Figure S5 Amino acid sequence alignment of PfAARP gene
sequenced from five P. falicparum laboratory strains and five field
isolates. Amino acids that are identical in at least six of the ten
sequences (.60%) are shown in grey.
Found at: doi:10.1371/journal.pone.0001732.s005 (8.44 MB TIF)
Table S1 Table showing details of P. falciparum strains and field
isolates used for sequencing of PfAARP genes
Found at: doi:10.1371/journal.pone.0001732.s006 (0.04 MB
DOC)
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